The Landmark Series: The Future of Pancreatic Cancer Clinical Trials

Keyphrases

• Pancreatic Cancer 100%
• Cancer Clinical Trials 100%
• Response Assessment 40%
• Poor Prognosis 20%
• Systemic Therapy 20%
• Patient Selection 20%
• Radiotherapy 20%
• Overall Survival 20%
• Combined Modality Therapy 20%
• Targeted Therapy 20%
• Response to Therapy 20%
• Prognostic Biomarker 20%
• Treatment Selection 20%
• Patient Outcomes 20%
• Treatment Paradigms 20%
• Anatomic 20%
• Treatment Decisions 20%
• Optimal Treatment 20%
• Circulating Tumor DNA (ctDNA) 20%
• Review Analysis 20%
• Preoperative Therapy 20%
• New Therapeutic Approaches 20%
• Genomic Data 20%
• Assessment Techniques 20%
• Dynamic Response 20%
• Adaptive Clinical Trial Design 20%
• Meaningful Improvement 20%
• Platform Trials 20%
• Time Assessment 20%
• Perioperative Therapy 20%
• Basket Trial 20%
• Radiomics 20%
• KRAS Inhibitors 20%
• Precision Oncology 20%
• Transcriptomic Data 20%
• Evolving Strategy 20%
• Biological Heterogeneity 20%
• Clinical Trial Landscape 20%

Medicine and Dentistry

• Clinical Trial 100%
• Pancreas Cancer 100%
• Biological Marker 20%
• Diseases 20%
• Decision Making 20%
• Targeted Therapy 20%
• Overall Survival 20%
• Radiation Therapy 20%
• Biological Product 20%
• Patient Selection 20%
• Transcriptomics 20%
• Clinical Trial Design 20%
• Circulating Tumor DNA 20%
• Radiomics 20%
• Precision Oncology 20%
• Genetics 20%
• Long-Term Outcome 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Clinical Trial 100%
• Pancreas Cancer 100%
• Diseases 20%
• Overall Survival 20%
• Biological Marker 20%
• Biological Product 20%
• Clinical Trial Design 20%
• Circulating Tumor DNA 20%